Congress Locks In $48.7 Billion for NIH and Blocks Indirect Cost Cap
March 6, 2026 · 2 min read
Arthur Griffin
Congress has finalized NIH's FY2026 budget at $48.7 billion in discretionary funding — a $415 million increase over FY2025 that represents a bipartisan rejection of the Trump administration's proposed 40% cut to the nation's largest biomedical research funder.
The Indirect Cost Cap That Didn't Happen
Beyond the topline number, the spending bill includes language that explicitly blocks the administration's proposed 15% cap on indirect cost reimbursement rates. The provision extends across all Department of Health and Human Services research agencies, preventing changes to negotiated rates that universities and research institutions depend on to fund infrastructure, administration, and facilities.
The indirect cost fight has been a defining battle for research universities since the administration first floated the cap in early 2025. A 15% ceiling would have effectively slashed total grant value by 20–30% at many institutions, where negotiated rates typically run between 40% and 60%. Congress's decision to block the cap provides at least one year of certainty for institutional budgeting.
What $415 Million More Actually Means
A $415 million increase on a $48.3 billion base amounts to roughly a 0.9% nominal bump — below inflation, meaning NIH's purchasing power continues to erode. But context matters: the administration had sought to cut the budget to approximately $29 billion. The final number represents a $19.7 billion gap between what the White House wanted and what Congress delivered.
For individual investigators, flat real-dollar funding means paylines remain tight. NIH institutes will need to balance commitments to multi-year awards already in the pipeline against new R01 and R21 competitions. Early-career researchers face continued pressure, though specific set-aside programs for new investigators remain funded.
Next Steps for Biomedical Researchers
Standard NIH submission deadlines continue on their regular cycle: June 5 for new R01/R21 applications, October 5 for renewals. The blocked indirect cost cap means budgets can be prepared using current negotiated rates without hedging for a possible cut.
In-depth analysis of NIH funding trends and complementary grant opportunities is available on the Granted blog.